iPSC eye-cell transplant for late dry macular degeneration
Part of Eyes & vision clinical trials.
This Phase 1 study tests an experimental transplant made from your own cells to try to improve vision in people with advanced “late dry” age-related macular degeneration (AMD). It focuses first on safety, and may help some participants with limited central vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 50 to 75 years old
- You have advanced “late dry” AMD with specific damage in the center vision area (the fovea) and/or stubborn “wet” AMD that did not respond to standard treatment
- Your target eye’s vision (BCVA) is between 0.05 and 0.3 (so you still have some measurable vision but not normal vision)
- You are able to give informed consent and attend regular follow-up visits on schedule
- You are not relying on medications or conditions that increase bleeding, infection risk, or immune risk during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.
This trial tests a new approach to improve vision in people with end-stage age-related macular degeneration (AMD). It aims to help those whose vision has dropped to a moderate or severe level, even with glasses, and who are not contact lens wearers.
This early-phase study tests whether transplanting lab-made retinal cells from your own body can slow vision loss from geographic atrophy caused by dry age-related macular degeneration. It involves eye surgery and frequent follow-up to check safety and early signs of benefit.
This trial tests if transplanting lab-grown retinal cells (RPE cells) into the eye can help people with late-stage dry AMD. It aims to slow vision loss and possibly improve sight.
This early-stage study tests whether a stem-cell–derived transplant to the back of the eye is safe and tolerable in people with dry age-related macular degeneration (AMD). If you qualify, you may receive the transplant and have close follow-up to watch for side effects.
This trial tests if using your own stem cells to create retinal cells can help treat advanced age-related macular degeneration (AMD). If you have severe vision loss from AMD, this approach may restore some sight.
Hear when a new Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.